All In Biotech

Drug Trial Radar · NCT07433387

Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals

An Exploratory Multicenter, Open-label, Sequential Cohort Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacokinetic Characteristics of LP-98 forInjection in Antiretroviral Therapy-Naive HIV-Infected Individuals

Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

30

Planned (sponsor's estimate)

Start

Jan 29, 2026

Primary completion

Jul 10, 2026

Study completion Sep 25, 2026

Sponsor

Sponsor type
Industry
Collaborators
Institute of Pathogen Biology, Beijing, China
First posted
Feb 25, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

An Exploratory Multicenter, Open-label, Sequential Cohort Study to Evaluate the Preliminary Efficacy, Safety, and Pharmacokinetic Characteristics of LP-98 for Injection in Antiretroviral Therapy-Naive HIV-Infected Individuals

Conditions

  • HIV

Interventions

  • LP-98 20 mgDrug

    The study plans to enroll a total of 30 subjects, with 10 subjects in each cohort. Enrolled subjects will receive LP-98 treatment at doses of 20 mg, 40 mg, or 80 mg according to their assigned cohort. The drug will be administered via subcutaneous injection, with an interval of 14 days between doses, for a total of 4 doses.

  • LP-98 40 mgDrug

    LP-98 40 mg

  • LP-98 80 mgDrug

    LP-98 80 mg

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Plasma HIV RNA levels (log10 copies/mL) and changes from baselineTime frame: Within 71 days after the first administration.
  2. Proportion of subjects with plasma HIV RNA < 50 copies/mLTime frame: Within 71 days after the first administration.
  3. Proportion of subjects with plasma HIV RNA < 200 copies/mLTime frame: Within 71 days after the first administration.
  4. Absolute CD4+ T lymphocyte count and change from baselineTime frame: Within 71 days after the first administration.
  5. CD4+/CD8+ T lymphocyte ratio and change from baselineTime frame: Within 71 days after the first administration.

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Tianjin Second People's Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.